Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review)

  • Authors:
    • Atsushi Imai
    • Satoshi Ichigo
    • Kazutoshi Matsunami
    • Hiroshi Takagi
    • Ichiro Kawabata
  • View Affiliations

  • Published online on: May 5, 2017     https://doi.org/10.3892/mco.2017.1237
  • Pages: 807-810
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Improvements in cancer therapy have enabled further insight into the long‑term effects of treatment, including the highly prevalent gonadal failure. The focus of treatment has been shifted to the preservation of fertility, which may be achieved by preventing ovarian toxicity. To this end, new molecular‑targeted agents, including monoclonal antibodies, have been developed and used in a standard procedure for managing different cancers. However, the prolonged antitumor activity of these drugs may cause the emergence of new toxic effects. The aim of the present review was to discuss the leading toxic effect of the anti-angiogenic agent bevacizumab on ovarian function in female patients of reproductive age, which may be observed and expected during in clinical practice. The majority of bevacizumab-induced side effects are expected to be transient and eliminated within the anticipated drug clearance time frame; however, fundamental investigations on these effects are required for generating more evidence-based practice guidelines.
View Figures
View References

Related Articles

Journal Cover

June-2017
Volume 6 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Imai A, Ichigo S, Matsunami K, Takagi H and Kawabata I: Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review). Mol Clin Oncol 6: 807-810, 2017
APA
Imai, A., Ichigo, S., Matsunami, K., Takagi, H., & Kawabata, I. (2017). Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review). Molecular and Clinical Oncology, 6, 807-810. https://doi.org/10.3892/mco.2017.1237
MLA
Imai, A., Ichigo, S., Matsunami, K., Takagi, H., Kawabata, I."Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review)". Molecular and Clinical Oncology 6.6 (2017): 807-810.
Chicago
Imai, A., Ichigo, S., Matsunami, K., Takagi, H., Kawabata, I."Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review)". Molecular and Clinical Oncology 6, no. 6 (2017): 807-810. https://doi.org/10.3892/mco.2017.1237